Dr Reddys Laboratories shares gained 2.02% to trade at Rs 1,245 at 12:20 pm on Wednesday. The stock's performance reflects a positive movement from its previous close.
Financial Performance:
The following table presents the consolidated quarterly financial performance of Dr Reddys Laboratories:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 7,696.10 Crore | Rs 8,038.20 Crore | Rs 8,381.20 Crore | Rs 8,528.40 Crore | Rs 8,572.10 Crore |
| Net Profit | Rs 1,386.50 Crore | Rs 1,335.80 Crore | Rs 1,400.00 Crore | Rs 1,581.20 Crore | Rs 1,409.70 Crore |
| EPS | 83.61 | 80.45 | 16.97 | 19.12 | 17.04 |
The revenue for the quarter-ending June 2025 was Rs 8,572.10 Crore, an increase compared to Rs 7,696.10 Crore in the quarter-ending June 2024. The net profit for the quarter-ending June 2025 was Rs 1,409.70 Crore, compared to Rs 1,386.50 Crore for the quarter-ending June 2024.
The following table presents the consolidated yearly financial performance:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 19,047.50 Crore | Rs 21,545.20 Crore | Rs 24,669.70 Crore | Rs 28,011.10 Crore | Rs 32,643.90 Crore |
| Net Profit | Rs 1,903.60 Crore | Rs 2,112.20 Crore | Rs 4,470.30 Crore | Rs 5,563.20 Crore | Rs 5,703.50 Crore |
| EPS | 117.67 | 131.57 | 271.47 | 335.22 | 67.89 |
| BVPS | 1,060.20 | 1,154.59 | 1,397.73 | 1,693.93 | 402.27 |
| ROE | 11.06 | 11.35 | 19.35 | 19.74 | 16.85 |
| Debt to Equity | 0.15 | 0.16 | 0.05 | 0.06 | 0.12 |
The revenue for the year-ending March 2025 increased to Rs 32,643.90 Crore compared to Rs 28,011.10 Crore in the year-ending March 2024. Net profit for the year-ending March 2025 also increased to Rs 5,703.50 Crore compared to Rs 5,563.20 Crore in the year-ending March 2024.
Consolidated Yearly Income Statement:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | 32,643 | 28,011 | 24,669 | 21,545 | 19,047 |
| Other Income | 1,097 | 894 | 1,055 | 484 | 291 |
| Total Income | 33,741 | 28,905 | 25,725 | 22,029 | 19,338 |
| Total Expenditure | 25,800 | 21,548 | 19,570 | 18,942 | 16,406 |
| EBIT | 7,940 | 7,357 | 6,154 | 3,086 | 2,932 |
| Interest | 282 | 171 | 142 | 95 | 97 |
| Tax | 1,954 | 1,623 | 1,541 | 878 | 931 |
| Net Profit | 5,703 | 5,563 | 4,470 | 2,112 | 1,903 |
Consolidated Quarterly Income Statement:
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|
| Sales | 8,572 | 8,528 | 8,381 | 8,038 | 7,696 |
| Other Income | 290 | 522 | 150 | 307 | 187 |
| Total Income | 8,862 | 9,050 | 8,531 | 8,345 | 7,883 |
| Total Expenditure | 6,874 | 6,985 | 6,579 | 6,358 | 5,946 |
| EBIT | 1,987 | 2,065 | 1,951 | 1,987 | 1,936 |
| Interest | 83 | 65 | 81 | 75 | 59 |
| Tax | 495 | 418 | 470 | 575 | 490 |
| Net Profit | 1,409 | 1,581 | 1,400 | 1,335 | 1,386 |
Cash Flow:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | 4,642 | 4,543 | 5,887 | 2,810 | 3,570 |
| Investing Activities | -5,807 | -4,028 | -4,137 | -2,638 | -2,266 |
| Financing Activities | 1,891 | -376 | -2,686 | -242 | -29 |
| Others | 22 | -5 | 28 | 73 | 11 |
| Net Cash Flow | 748 | 132 | -907 | 3 | 1,285 |
Balance Sheet:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | 83 | 83 | 83 | 83 | 83 |
| Reserves & Surplus | 33,466 | 28,171 | 23,202 | 19,129 | 17,558 |
| Current Liabilities | 13,033 | 9,588 | 8,572 | 9,765 | 8,103 |
| Other Liabilities | 2,843 | 1,021 | 426 | 768 | 871 |
| Total Liabilities | 49,426 | 38,863 | 32,285 | 29,746 | 26,616 |
| Fixed Assets | 19,378 | 11,294 | 9,701 | 8,867 | 9,210 |
| Current Assets | 25,018 | 24,805 | 20,425 | 17,782 | 14,550 |
| Other Assets | 5,030 | 2,763 | 2,157 | 3,097 | 2,855 |
| Total Assets | 49,426 | 38,863 | 32,285 | 29,746 | 26,616 |
| Contingent Liabilities | 1,738 | 2,091 | 997 | 936 | 1,077 |
Financial Ratios:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 67.89 | 335.22 | 271.47 | 131.57 | 117.67 |
| Diluted Eps (Rs.) | 67.79 | 334.59 | 270.90 | 131.21 | 117.34 |
| Book Value /Share (Rs.) | 402.27 | 1,693.93 | 1,397.73 | 1,154.59 | 1,060.20 |
| Dividend/Share (Rs.) | 8.00 | 40.00 | 40.00 | 30.00 | 25.00 |
| Face Value | 1 | 5 | 5 | 5 | 5 |
| Gross Profit Margin (%) | 29.54 | 31.51 | 30.01 | 19.73 | 21.84 |
| Operating Margin (%) | 24.32 | 26.26 | 24.94 | 14.32 | 15.39 |
| Net Profit Margin (%) | 17.47 | 19.86 | 18.12 | 9.80 | 9.99 |
| Return on Networth / Equity (%) | 16.85 | 19.74 | 19.35 | 11.35 | 11.06 |
| ROCE (%) | 21.81 | 25.13 | 25.95 | 15.44 | 15.84 |
| Return On Assets (%) | 11.44 | 14.35 | 13.96 | 7.33 | 7.33 |
| Current Ratio (X) | 1.92 | 2.59 | 2.38 | 1.82 | 1.80 |
| Quick Ratio (X) | 1.37 | 1.92 | 1.82 | 1.30 | 1.24 |
| Debt to Equity (x) | 0.12 | 0.06 | 0.05 | 0.16 | 0.15 |
| Interest Coverage Ratios (X) | 34.09 | 51.59 | 51.85 | 44.39 | 42.90 |
| Asset Turnover Ratio (%) | 0.74 | 0.79 | 0.80 | 0.56 | 0.60 |
| Inventory Turnover Ratio (X) | 0.84 | 0.80 | 0.85 | 0.86 | 1.03 |
| 3 Yr CAGR Sales (%) | 23.09 | 21.27 | 18.67 | 18.10 | 15.49 |
| 3 Yr CAGR Net Profit (%) | 64.32 | 70.95 | 50.64 | 5.26 | 44.44 |
| P/E (x) | 16.85 | 3.67 | 3.41 | 6.53 | 7.68 |
| P/B (x) | 2.84 | 3.63 | 3.31 | 3.73 | 4.26 |
| EV/EBITDA (x) | 10.11 | 11.62 | 10.32 | 17.01 | 18.20 |
| P/S (x) | 2.92 | 3.67 | 3.12 | 3.33 | 3.94 |
Corporate Actions:
Dr Reddys Laboratories announced updates under Regulation 30 of SEBI LODR Regulations, 2015, on August 8, 2025. The company announced a final dividend of Rs 8 per share on May 9, 2025, which was effective from July 10, 2025.
The company has also issued bonus shares in the past. The most recent bonus issue was on May 31, 2006, with a bonus ratio of 1:1 and an ex-bonus date of August 28, 2006. The company had splits where old FV of 5 is converted to new FV of 1, and exsplit date is on October 28, 2024.
Moneycontrol analysis indicates very bearish sentiment on the stock as of August 13, 2025.
With the stock currently trading at Rs 1,245, Dr Reddys Laboratories demonstrates a positive movement in today's session.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
